The Company is incorporated in France with registered no. 491 062 527.
In addition, it has direct and indirect subsidiaries in the UK, with further operations in the US and in Asia Pacific and its products are distributed to and sold across multiple jurisdictions.
The Company is admitted to trading on the AIM market of the London Stock Exchange and listed on Euronext Growth Paris.
The Company is subject to the applicable laws and regulations of France, as well as the regulatory framework that applies to the French and AIM stock markets.
13 Avenue Morane Saulnier
78140 Vélizy-Villacoublay
France
Click here to view the Novacyt articles of association >>
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.
The Company is divided into three business segments:
Clinical:
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
• Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
• Precision Medicine: DPYD genotyping assay
• Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation:
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
• Ranger® Technology: automated DNA sample preparation and target enrichment technology
• MyGo: real-time quantitative PCR (qPCR) instruments
Research Use Only
Range of services for the life sciences industry:
• Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
• Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)
The Board comprises of three Executive Directors and four Non-executive Directors.
Lyn Rees, Chief Executive Director
Dr Joanne Mason, Chief Scientific Officer
Steve Gibson, Chief Financial Officer
Jean-Pierre Crinelli, Independent Non-Executive Director
John Brown, Independent Non-Executive Director
Juliet Thompson, Chair of the Audit Committee
James Wakefield, Non-executive Director and Chairman of the Board
Novacyt S.A. is listed on the Euronext Growth Paris (formerly known as Alternext Paris) and is admitted to trading on the AIM market of the London Stock Exchange.
Rule 17 of the AIM Rules requires, inter alia, that shareholders notify an AIM listed company once their holding is three per cent or more, and changes thereto (movements through a percentage point upwards or downwards).
As as 01.06.2024 there are no significant shareholdings of 3% or more.
Director shareholdings:
| Director | Shares Held | % of Issued Share Capital |
|---|---|---|
| James Wakefield | 43,839 | 0.06% |
| Jean-Pierre Crinelli | 33,981 | 0.05% |
| Steve Gibson & Family | 9,116 | 0.01% |
Last updated on 12.09.24
The rights of the Company’s shareholders may be different from the rights of shareholders in a UK incorporated company.
There are no restrictions on transfer of securities.
Click here to view Financial reports.
Click here to view company announcements >>
The Company is not subject to the UK City Code on Takeovers and Mergers. However, French law contains provisions relating to takeovers of certain companies, including the Company.
The General Regulation of the Autorité Des Marchés Financiers of France (the AMF) applies to the Company, as it is a public limited company whose shares were first admitted to trading on Euronext Growth Paris, if an acquisition of hares in such a company were to increase the aggregate holding of the acquirer and its concert parties to interests in shares carrying 50 per cent. or more of the share capital or voting rights in the company, the acquirer and its concert parties would be required (except with the consent of the AMF) to make a cash offer for the outstanding shares at a price not less than the highest price paid for the shares by the acquirer or its concert parties during the previous twelve months.
To view our advisors please click here
Click the link below to view Novacyt’s AIM admission document
Further information about our Corporate Governance click here
For Investor Relations Support for the Novacyt Group, please click the button below to contact our team.
